



5th June 2020

Newsletter

PROHIBIT-ICH

Prevention Of Hypertensive Injury to the Brain by Intensive Treatment in IntraCerebral Haemorrhage

Dear all PROHIBIT-ICH collaborators,
We would like to thank you for your continued support during this challenging time.

RECRUITMENT UPDATE

- **Total recruitment: 36 participants**
- **Recruitment target: 112 participants**
- **Recruitment is paused but the Trial Management Group are working to resume recruitment with guidance from the relevant authorities.**

Please keep a **screening log** of potentially eligible participants or a list of ICH patients if you have staff capacity issues.

FOLLOW UP VISITS

3 month follow up visit – to be done remotely if your site does not allow in person visits yet

- **24 hr ABPM should still happen as scheduled. Please contact the Oxford team by email for guidance in advance of the visit.**
- **For cognitive assessment, use 22 point telephone MoCA instead.**

12 month follow up visit – all parts of the visit are postponed until MRI scanners are available at your site.

- **The visit should happen as close as possible to the scheduled visit, once restrictions are lifted.**
- **Please delay eCRF completion until then.**

You can find further details in the **Contingency Plan** on our website www.prohibit-ich.org.uk

LOOKING TO THE FUTURE

For recruitment to restart, please can you begin to consider the following factors:

1. Viability
2. Safety of research staff & participants
3. Capacity and readiness of site services
4. Prioritisation of studies

These are discussed in detail in the NIHR's Restart Framework, which is well worth a read:

www.nihr.ac.uk/documents/restart-framework/24886

COVID-19 RELATED REQUESTS

Please continue to send us any news or updates from your R&D and MRI departments about when recruitment and 12 month follow up visits can resume.

Please let us know if you experience any difficulties at your site that we may be able to help with.

Stay in touch and stay safe everyone!

www.prohibit-ich.org.uk

Kind regards,

Maja Dabagh
Study Co-ordinator

David Werring
Chief Investigator

Peter Rothwell
Co-Chief Investigator

Iain McGurgan
Research Fellow

Michelle Wilson
BP Co-ordinator

